
QLT Inc. has halted a randomized, placebo-controlled, double-masked phase II proof-of-concept trial of an olopatadine (Patanol, Alcon) punctal plug delivery system (O-PPDS) after the study model ?could not generate definitive clinical results,? according to company officials.
